Services

BioRunUp


Visit BioRunUp Now!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

Black Service


Visit the Black Service!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

Tim Alerts



Visit Timothy Sykes!

 In 2010 BioRunUp was created by Mark Messier and Mike Harvilla, two highly successful bio-tech stock traders. The company employs a trading strategy known as the “run-up” method – taking advantage of bullish movements in biotech stocks before key FDA events. This service provides alerts, reports, valuation models, watch lists and members only forum.

Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. These volatile catalysts present an excellent opportunity for traders to profit.

.



Stock Gravity's Recent Tweets

  • That $38 floor will crater when all of the sheeple bids are used up. Bernanke probably bought at the high today too. #Facebook 1 day ago

  • FB was never designed to make money. The second you start to charge for services once free people go elsewhere. Mark knows. Analysts don't! 2 days ago

  • $FB overvalued by 20x ...yes seriously 2 days ago

  • Facebook will be the most overvalued stock in history. What market will they take over? Smart phone, retail, advertising, gaming? No no no! 2 days ago

  • $APPL is a great long term buy, but there is no rush. Let the momo traders and bag holders exit first. Buy 50-100 pts lower... 2 days ago

  • It's depressing seeing so many people recommending buying $APPL. We know you all bought at the top - you aren't fooling anyone. #Bagholders 2 days ago

  • @Sqwii Still nothing? You got a few upticks this week to dump. 2 weeks ago

  • RT @Not_Jim_Cramer: At drivers license bureau and realizing 70% of US has a tattoo and is mentally retarded 2 weeks ago

  • @Sqwii What is your average cost per share on $TVIX with the double downs you recommend to subs? 2 months ago

  • Chinese companies under pressure as Deloitte mulls dropping accounting coverage of $CAST - Nasdaq suspends trading. 2 months ago

Gold & Silver Coins